$6.31
0.010000.16%
At close: -
$6.41
0.101.58%
After Hours: 7:56 PM EDT
Comments
Loading...
Day One Biopharmaceutical Insider Trading Activity | NASDAQ:DAWN | Benzinga
Track the latest Day One Biopharmaceutical insider trading activity. Stay informed on recent buys, sells, and market impact for Day One Biopharmaceutical stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Day One Biopharmaceuticals Inc Insiders Doing?
At Day One Biopharmaceuticals Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of - shares worth -, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
There has been no Insider buying or selling in the last 90 days.
Ownership Statistics for Day One Biopharmaceuticals Inc
Shares Outstanding
101.362M
Insider Shares Owned
1.658M
Insider Percentage Owned
1.64%
Institutional Shares Held
49.744M
Institutional Percentage Held
49.1%
| May 19, 2025 | Lauren Merendino | CHIEF COMMERCIAL OFFICER | 6.61K | $6.26 | -$24.57K | SELL-OPTIONS | 23.15% | 35.16K | May 15 - May 16 | View |
| May 19, 2025 | Adam Dubow | GENERAL COUNSEL | 7.53K | $6.26 | -$28.49K | SELL-OPTIONS | 19.02% | 47.14K | May 15 - May 16 | View |
| May 19, 2025 | Charles N. York II | COO, CFO AND SECRETARY | 12.59K | $6.26 | -$26.80K | SELL-OPTIONS | 4.98% | 265.23K | May 15 - May 16 | View |
| May 19, 2025 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 17.72K | $6.26 | -$87.39K | SELL-OPTIONS | 1.90% | 952.76K | May 15 - May 16 | View |
| Feb 21, 2025 | Charles N. York II | COO, CFO AND SECRETARY | 12.51K | $11.96 | -$52.28K | SELL-OPTIONS | 5.21% | 252.64K | Feb 15 - Feb 18 | View |
| Feb 21, 2025 | Adam Dubow | GENERAL COUNSEL | 7.44K | $11.96 | -$55.58K | SELL-OPTIONS | 23.13% | 39.60K | Feb 15 - Feb 18 | View |
| Feb 21, 2025 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 19.64K | $11.96 | -$144.13K | SELL-OPTIONS | 2.15% | 935.04K | Feb 15 - Feb 18 | View |
| Dec 12, 2024 | Samuel Blackman | HEAD OF R&D | -30.00K | $13.31 | -$399.34K | SELL | -1.45% | 2.03M | Dec 10 | View |
| Nov 19, 2024 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 9.45K | $13.21 | -$139.42K | SELL-OPTIONS | 1.04% | 915.40K | Nov 15 - Nov 18 | View |
| Nov 19, 2024 | Samuel Blackman | HEAD OF R&D | 6.48K | $13.21 | -$29.14K | SELL-OPTIONS | 0.31% | 2.06M | Nov 15 - Nov 18 | View |
| Nov 19, 2024 | Adam Dubow | GENERAL COUNSEL | 5.23K | $13.21 | -$41.81K | SELL-OPTIONS | 19.44% | 32.16K | Nov 15 - Nov 18 | View |
| Nov 19, 2024 | Charles N. York II | COO, CFO AND SECRETARY | 7.65K | $13.21 | -$34.37K | SELL-OPTIONS | 3.29% | 240.13K | Nov 15 - Nov 18 | View |
| Nov 12, 2024 | Samuel Blackman | HEAD OF R&D | -28.25K | $16.15 | -$456.22K | SELL | -1.35% | 2.06M | Nov 08 - Nov 11 | View |
| Nov 08, 2024 | Samuel Blackman | HEAD OF R&D | -11.24K | $16.03 | -$180.29K | SELL | -0.54% | 2.09M | Nov 07 | View |
| Nov 04, 2024 | Samuel Blackman | HEAD OF R&D | -500.00 | $16.02 | -$8.01K | SELL | -0.02% | 2.10M | Oct 31 | View |
| Sep 12, 2024 | Samuel Blackman | HEAD OF R&D | -30.00K | $14.22 | -$426.68K | SELL | -1.41% | 2.10M | Sep 10 | View |
| Aug 19, 2024 | Adam Dubow | GENERAL COUNSEL | 5.20K | $14.00 | -$44.83K | SELL-OPTIONS | 23.92% | 26.93K | Aug 15 - Aug 16 | View |
| Aug 19, 2024 | Charles N. York II | COO, CFO AND SECRETARY | 7.62K | $14.00 | -$36.86K | SELL-OPTIONS | 3.39% | 232.49K | Aug 15 - Aug 16 | View |
| Aug 19, 2024 | Samuel Blackman | HEAD OF R&D | 6.45K | $14.00 | -$31.25K | SELL-OPTIONS | 0.30% | 2.13M | Aug 15 - Aug 16 | View |
| Aug 19, 2024 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 9.32K | $14.00 | -$149.52K | SELL-OPTIONS | 1.04% | 905.96K | Aug 15 - Aug 16 | View |
| Jul 17, 2024 | Samuel Blackman | HEAD OF R&D | -20.00K | $16.01 | -$320.23K | SELL | -0.93% | 2.12M | Jul 16 | View |
| Jun 21, 2024 | Saira Ramasastry | — | -10.00K | $13.19 | -$131.88K | SELL | -19.81% | 40.48K | Jun 21 | View |
| Jun 12, 2024 | Samuel Blackman | HEAD OF R&D | -30.00K | $12.62 | -$378.59K | SELL | -1.38% | 2.14M | Jun 10 | View |
| May 17, 2024 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 12.13K | $16.08 | -$126.59K | SELL-OPTIONS | 1.33% | 924.95K | May 15 - May 16 | View |
| May 17, 2024 | Samuel Blackman | HEAD OF R&D | 6.42K | $16.08 | -$36.45K | SELL-OPTIONS | 0.30% | 2.17M | May 15 - May 16 | View |
| May 17, 2024 | Charles N. York II | COO, CFO AND SECRETARY | 7.58K | $16.08 | -$43.01K | SELL-OPTIONS | 3.49% | 224.87K | May 15 - May 16 | View |
| May 17, 2024 | Adam Dubow | GENERAL COUNSEL | 5.15K | $16.08 | -$52.30K | SELL-OPTIONS | 31.03% | 21.73K | May 15 - May 16 | View |
| May 14, 2024 | Samuel Blackman | HEAD OF R&D | -10.00K | $16.37 | -$163.74K | SELL | -0.46% | 2.16M | May 10 | View |
| May 03, 2024 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -79.21K | $17.87 | -$1.42M | SELL | -7.98% | 912.83K | May 01 - May 03 | View |
| May 03, 2024 | Charles N. York II | COO, CFO AND SECRETARY | -60.46K | $17.88 | -$1.08M | SELL | -21.77% | 217.29K | May 01 - May 03 | View |
| Apr 22, 2024 | Samuel Blackman | HEAD OF R&D | -10.00K | $16.02 | -$160.16K | SELL | -0.46% | 2.17M | Apr 18 | View |
| Mar 26, 2024 | Samuel Blackman | HEAD OF R&D | -10.00K | $16.01 | -$160.06K | SELL | -0.46% | 2.18M | Mar 25 | View |
| Mar 13, 2024 | Samuel Blackman | HEAD OF R&D | -30.00K | $15.24 | -$457.31K | SELL | -1.35% | 2.19M | Mar 11 | View |
| Feb 28, 2024 | Samuel Blackman | HEAD OF R&D | -20.00K | $16.11 | -$322.17K | SELL | -0.89% | 2.22M | Feb 27 | View |
| Feb 20, 2024 | Adam Dubow | GENERAL COUNSEL | 5.16K | $15.25 | -$49.43K | SELL-OPTIONS | 45.13% | 16.59K | Feb 15 - Feb 16 | View |
| Feb 20, 2024 | Charles N. York II | COO, CFO AND SECRETARY | 7.58K | $15.25 | -$40.65K | SELL-OPTIONS | 2.81% | 277.75K | Feb 15 - Feb 16 | View |
| Feb 20, 2024 | Samuel Blackman | HEAD OF RESEARCH AND DEVELOPME | 6.43K | $15.25 | -$34.43K | SELL-OPTIONS | 0.29% | 2.24M | Feb 15 - Feb 16 | View |
| Feb 20, 2024 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 12.38K | $15.25 | -$116.11K | SELL-OPTIONS | 1.26% | 992.04K | Feb 15 - Feb 16 | View |
| Nov 17, 2023 | Charles N. York II | COO, CFO AND SECRETARY | 2.67K | $11.69 | -$11.18K | SELL-OPTIONS | 1.00% | 270.17K | Nov 15 - Nov 16 | View |
| Nov 17, 2023 | Adam Dubow | GENERAL COUNSEL | 8.29K | $11.69 | -$62.11K | SELL-OPTIONS | 263.83% | 11.43K | Nov 15 - Nov 16 | View |
| Nov 17, 2023 | Samuel Blackman | HEAD RESEARCH AND DEVELOPME | 1.92K | $11.69 | -$8.29K | SELL-OPTIONS | 0.09% | 2.24M | Nov 15 - Nov 16 | View |
| Nov 17, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 5.21K | $11.69 | -$36.32K | SELL-OPTIONS | 0.53% | 979.65K | Nov 15 - Nov 16 | View |
| Oct 20, 2023 | AI Day LLCAccess Industries Holdings LLCACCESS INDUSTRIES MANAGEMENT LLCLen Blavatnik | 10% OWNER | 1.48M | $10.15 | $14.98M | BUY | 12.88% | 12.93M | Oct 18 - Oct 20 | View |
| Aug 17, 2023 | Charles N. York II | COO, CFO AND SECRETARY | 2.70K | $13.86 | -$12.78K | SELL-OPTIONS | 1.02% | 267.50K | Aug 15 - Aug 17 | View |
| Aug 17, 2023 | Samuel Blackman | HEAD RESEARCH AND DEVELOPME | 1.96K | $13.86 | -$9.26K | SELL-OPTIONS | 0.09% | 2.24M | Aug 15 - Aug 17 | View |
| Aug 17, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 5.32K | $13.86 | -$41.52K | SELL-OPTIONS | 0.55% | 974.45K | Aug 15 - Aug 17 | View |
| Jun 12, 2023 | AI Day LLCAccess Industries Holdings LLCACCESS INDUSTRIES MANAGEMENT LLCLen Blavatnik | 10% OWNER | 769.23K | $13.00 | $10.00M | BUY | 7.20% | 11.45M | Jun 09 | View |
| Jun 07, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | -1.23K | $16.00 | -$19.66K | SELL | -0.05% | 2.23M | Jun 05 | View |
| May 17, 2023 | Charles N. York II | COO, CFO AND SECRETARY | 2.67K | $13.12 | -$12.53K | SELL-OPTIONS | 1.02% | 264.80K | May 15 - May 16 | View |
| May 17, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | 1.93K | $13.12 | -$9.08K | SELL-OPTIONS | 0.09% | 2.24M | May 15 - May 16 | View |
| May 17, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 5.21K | $13.12 | -$40.73K | SELL-OPTIONS | 0.36% | 1.46M | May 15 - May 16 | View |
| Mar 14, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $18.05 | -$180.48K | SELL | -0.45% | 2.23M | Mar 10 | View |
| Mar 08, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.01 | -$250.11K | SELL | -0.85% | 1.46M | Mar 07 | View |
| Mar 03, 2023 | Papanek Julie Grant | DIRECTOR | -25.00K | $18.61 | -$465.30K | SELL | -0.86% | 2.88M | Mar 01 | View |
| Feb 21, 2023 | Charles N. York II | COO, CFO AND SECRETARY | -9.38K | $20.03 | -$187.79K | SELL | -3.45% | 262.13K | Feb 17 | View |
| Feb 17, 2023 | Charles N. York II | COO, CFO AND SECRETARY | 2.69K | $19.57 | -$18.20K | SELL-OPTIONS | 1.00% | 271.50K | Feb 15 - Feb 16 | View |
| Feb 17, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | 1.95K | $19.57 | -$13.19K | SELL-OPTIONS | 0.09% | 2.24M | Feb 15 - Feb 16 | View |
| Feb 17, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 5.29K | $19.57 | -$59.15K | SELL-OPTIONS | 0.36% | 1.47M | Feb 15 - Feb 16 | View |
| Feb 13, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $20.07 | -$200.66K | SELL | -0.44% | 2.24M | Feb 10 | View |
| Feb 03, 2023 | Papanek Julie Grant | DIRECTOR | -25.00K | $21.23 | -$530.79K | SELL | -0.85% | 2.90M | Feb 01 | View |
| Jan 24, 2023 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $22.00 | -$274.99K | SELL | -0.85% | 1.46M | Jan 23 | View |
| Jan 23, 2023 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $22.75 | -$227.52K | SELL | -3.59% | 268.81K | Jan 20 | View |
| Jan 11, 2023 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $22.86 | -$228.64K | SELL | -0.44% | 2.25M | Jan 10 | View |
| Jan 04, 2023 | Papanek Julie Grant | DIRECTOR | -25.00K | $20.65 | -$516.15K | SELL | -0.85% | 2.93M | Jan 03 | View |
| Dec 22, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.32 | -$253.97K | SELL | -0.84% | 1.47M | Dec 21 | View |
| Dec 22, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $20.07 | -$200.65K | SELL | -3.49% | 276.50K | Dec 20 | View |
| Dec 12, 2022 | Papanek Julie Grant | DIRECTOR | -4.36K | $22.08 | -$96.21K | SELL | -0.15% | 2.95M | Dec 08 | View |
| Dec 05, 2022 | Papanek Julie Grant | DIRECTOR | -10.00K | $21.65 | -$216.48K | SELL | -0.34% | 2.96M | Dec 01 - Dec 02 | View |
| Dec 05, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $21.45 | -$214.53K | SELL | -0.44% | 2.26M | Dec 01 | View |
| Nov 22, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $20.76 | -$207.57K | SELL | -3.37% | 286.50K | Nov 21 | View |
| Nov 22, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.76 | -$259.48K | SELL | -0.83% | 1.49M | Nov 21 | View |
| Nov 17, 2022 | Charles N. York II | COO, CFO AND SECRETARY | 945.00 | $21.46 | -$9.23K | SELL-OPTIONS | 0.32% | 296.50K | Nov 15 - Nov 16 | View |
| Nov 17, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | 810.00 | $21.46 | -$8.09K | SELL-OPTIONS | 0.04% | 2.27M | Nov 15 - Nov 16 | View |
| Nov 17, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 2.05K | $21.46 | -$32.47K | SELL-OPTIONS | 0.14% | 1.50M | Nov 15 - Nov 16 | View |
| Nov 03, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $20.03 | -$200.31K | SELL | -3.29% | 294.40K | Nov 01 | View |
| Nov 03, 2022 | Papanek Julie Grant | DIRECTOR | -10.00K | $20.03 | -$200.28K | SELL | -0.34% | 2.97M | Nov 01 - Nov 02 | View |
| Nov 03, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $20.00 | -$200.05K | SELL | -0.44% | 2.27M | Nov 01 | View |
| Nov 03, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.03 | -$250.36K | SELL | -0.83% | 1.50M | Nov 01 | View |
| Oct 05, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $20.05 | -$200.47K | SELL | -3.18% | 304.40K | Oct 03 | View |
| Oct 05, 2022 | Papanek Julie Grant | DIRECTOR | -10.00K | $20.03 | -$200.31K | SELL | -0.14% | 7.39M | Oct 03 - Oct 04 | View |
| Oct 05, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $19.99 | -$199.85K | SELL | -0.44% | 2.28M | Oct 03 | View |
| Oct 05, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.05 | -$250.65K | SELL | -0.82% | 1.51M | Oct 03 | View |
| Sep 22, 2022 | Canaan XI LPCanaan Partners XI LLC | 10% OWNER | -2.11M | $18.55 | -$11.38M | SELL | -23.28% | 6.96M | Sep 21 | View |
| Sep 22, 2022 | Papanek Julie Grant | DIRECTOR | -2.11M | $18.55 | -$11.38M | SELL | -23.28% | 6.97M | Sep 21 | View |
| Sep 20, 2022 | Papanek Julie Grant | DIRECTOR | -340.70K | $20.44 | -$6.96M | SELL | -3.62% | 9.08M | Sep 16 - Sep 20 | View |
| Sep 20, 2022 | Canaan XI LPCanaan Partners XI LLC | 10% OWNER | -340.70K | $20.44 | -$6.96M | SELL | -3.62% | 9.08M | Sep 16 - Sep 20 | View |
| Sep 15, 2022 | Papanek Julie Grant | DIRECTOR | -245.04K | $23.76 | -$5.82M | SELL | -2.54% | 9.42M | Sep 13 - Sep 15 | View |
| Sep 15, 2022 | Canaan XI LPCanaan Partners XI LLC | 10% OWNER | -245.04K | $23.76 | -$5.82M | SELL | -2.54% | 9.42M | Sep 13 - Sep 15 | View |
| Sep 15, 2022 | Julie Papanek Grant | DIRECTOR | -5.00K | $23.82 | -$119.11K | SELL | -0.05% | 10.10M | Sep 02 | View |
| Sep 06, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $23.25 | -$232.48K | SELL | -3.08% | 314.40K | Sep 01 | View |
| Sep 06, 2022 | Julie Papanek Grant | DIRECTOR | -5.00K | $23.27 | -$116.36K | SELL | -0.05% | 10.11M | Sep 01 | View |
| Sep 06, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $23.25 | -$232.45K | SELL | -0.43% | 2.29M | Sep 01 | View |
| Sep 06, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $23.25 | -$290.58K | SELL | -0.81% | 1.52M | Sep 01 | View |
| Sep 06, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $23.25 | -$290.58K | SELL | -0.81% | 1.52M | Sep 01 | View |
| Aug 17, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | 2.62K | $24.31 | -$22.88K | SELL-OPTIONS | 0.11% | 2.30M | Aug 15 - Aug 16 | View |
| Aug 17, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | 6.68K | $24.31 | -$97.31K | SELL-OPTIONS | 0.44% | 1.53M | Aug 15 - Aug 16 | View |
| Aug 17, 2022 | Charles N. York II | COO, CFO AND SECRETARY | 3.04K | $24.31 | -$26.47K | SELL-OPTIONS | 0.94% | 324.40K | Aug 15 - Aug 16 | View |
| Aug 08, 2022 | Julie Papanek Grant | DIRECTOR | -10.00K | $20.00 | -$200.00K | SELL | -0.10% | 10.11M | Aug 04 - Aug 05 | View |
| Aug 05, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -10.00K | $20.05 | -$200.54K | SELL | -3.02% | 321.37K | Aug 04 | View |
| Aug 05, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -12.50K | $20.00 | -$250.02K | SELL | -0.81% | 1.53M | Aug 04 | View |
| Aug 03, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $16.88 | -$168.81K | SELL | -0.43% | 2.30M | Aug 01 | View |
| Jul 20, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -2.50K | $20.00 | -$50.00K | SELL | -0.75% | 331.37K | Jul 18 | View |
| Jul 20, 2022 | Julie Papanek Grant | DIRECTOR | -2.60K | $20.00 | -$52.00K | SELL | -0.03% | 10.12M | Jul 18 | View |
| Jul 20, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -2.60K | $20.00 | -$52.00K | SELL | -0.17% | 1.54M | Jul 18 | View |
| Jul 12, 2022 | Julie Papanek Grant | DIRECTOR | -1.24K | $20.00 | -$24.84K | SELL | -0.01% | 10.13M | Jul 08 | View |
| Jul 12, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -1.42K | $20.00 | -$28.32K | SELL | -0.42% | 333.87K | Jul 08 | View |
| Jul 12, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -1.79K | $20.00 | -$35.90K | SELL | -0.12% | 1.54M | Jul 08 | View |
| Jul 06, 2022 | Charles N. York II | COO, CFO AND SECRETARY | -2.28K | $20.00 | -$45.58K | SELL | -0.68% | 335.28K | Jul 01 - Jul 05 | View |
| Jul 06, 2022 | Julie Papanek Grant | DIRECTOR | -1.80K | $20.00 | -$36.00K | SELL | -0.39% | 463.20K | Jul 01 - Jul 05 | View |
| Jul 06, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $18.72 | -$187.16K | SELL | -0.43% | 2.31M | Jul 01 | View |
| Jul 06, 2022 | Jeremy Bender | CHIEF EXECUTIVE OFFICER | -2.60K | $20.00 | -$52.06K | SELL | -0.17% | 1.54M | Jul 01 - Jul 05 | View |
| Jun 22, 2022 | Atlas Venture Opportunity Fund II LPAtlas Venture Fund XI LPAtlas Venture Associates XI LPAtlas Venture Associates XI LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LPAtlas Venture Associates Opportunity I LLC | 10% OWNER | 766.67K | $15.00 | $11.50M | BUY | 77.33% | 1.76M | Jun 17 | View |
| Jun 22, 2022 | Michael Gladstone | DIRECTOR | 766.67K | $15.00 | $11.50M | BUY | ∞ | 766.67K | Jun 17 | View |
| Jun 21, 2022 | AI Day LLCAccess Industries Holdings LLCACCESS INDUSTRIES MANAGEMENT LLCLen Blavatnik | 10% OWNER | 1.20M | $15.00 | $18.00M | BUY | 12.65% | 10.68M | Jun 17 | View |
| Jun 17, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -50.00K | $16.26 | -$813.16K | SELL | -2.11% | 2.32M | Jun 15 | View |
| Jan 20, 2022 | AI Day LLCAccess Industries Holdings LLCACCESS INDUSTRIES MANAGEMENT LLCLen Blavatnik | 10% OWNER | 106.86K | $14.52 | $1.55M | BUY | 1.14% | 9.48M | Jan 18 - Jan 20 | View |
| Jan 05, 2022 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $17.10 | -$171.02K | SELL | -0.42% | 2.37M | Jan 03 | View |
| Dec 09, 2021 | TAKEDA PHARMACEUTICAL CO LTDTakeda Pharmaceuticals USA IncMILLENNIUM PHARMACEUTICALS INCTakeda Ventures Inc | 10% OWNER | -297.27K | $18.49 | -$5.50M | SELL | -4.63% | 6.12M | Dec 07 - Dec 08 | View |
| Dec 07, 2021 | TAKEDA PHARMACEUTICAL CO LTDTakeda Pharmaceuticals USA IncMILLENNIUM PHARMACEUTICALS INCTakeda Ventures Inc | 10% OWNER | -110.21K | $18.10 | -$1.99M | SELL | -1.69% | 6.42M | Dec 03 - Dec 06 | View |
| Dec 03, 2021 | Samuel Blackman | CHIEF MEDICAL OFFICER | -10.00K | $17.22 | -$172.24K | SELL | -0.72% | 1.38M | Oct 22 - Dec 01 | View |
| Jun 03, 2021 | AI Day LLCAccess Industries Holdings LLCACCESS INDUSTRIES MANAGEMENT LLCLen Blavatnik | 10% OWNER | 9.38M | $16.00 | $14.00M | BUY | ∞ | 9.38M | Jun 01 | View |
| Jun 02, 2021 | Julie Papanek Grant | DIRECTOR | 7.49M | $16.00 | $208.00K | BUY | 201.83% | 11.20M | Jun 01 | View |
| Jun 02, 2021 | Atlas Venture Fund XI LPAtlas Venture Associates Opportunity I LLCAtlas Venture Opportunity Fund I LPAtlas Venture Associates Opportunity I LPAtlas Venture Associates XI LPAtlas Venture Associates XI LLC | 10% OWNER | 9.00M | $16.00 | $8.00M | BUY | ∞ | 250.00K | Jun 01 | View |
| Jun 02, 2021 | Canaan XI LPCanaan Partners XI LLC | 10% OWNER | 7.49M | $16.00 | $208.00K | BUY | 230.75% | 10.74M | Jun 01 | View |
| Jun 01, 2021 | John Josey | DIRECTOR | 7.00K | $16.00 | $112.00K | BUY | 10.72% | 72.29K | Jun 01 | View |
| Jun 01, 2021 | Daniel Becker | DIRECTOR | 5.00K | $16.00 | $80.00K | BUY | ∞ | 5.00K | Jun 01 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
